Stockreport

Ziopharm Oncology Names NCI’s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program

ZIOPHARM Oncology Inc  (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
PDF BOSTON, July 03, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew Deniger, Ph.D., will join Ziopharm [Read more]